BioSpace News Archive

Atamyo Therapeutics Obtains First Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9.

Zynerba Pharmaceuticals , Inc. today announced presentation details for The BRAIN Foundation Synchrony 2021 Symposium, being held virtually December 11-12, 2021.

Amydis Inc. today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plans for a small-molecule tracer to detect TDP43 in the retina of amyotrophic lateral sclerosis (ALS) patients.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that " embecta " [pronounced em-BECK-tah] will be the name of the independent, publicly-traded company that will hold BD’s Diabetes Care business upon the completion of the previously announced spinoff.

Gritstone bio, Inc. and CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of their agreement in order to support the development of a self-amplifying mRNA (SAM) vaccine designed to tackle the Omicron COVID-19 variant.

Helius Medical Technologies, Inc. today announced that Chief Medical Officer Antonella Favit-Van Pelt, M.D., Ph.D. will be presenting at the 4th International Brain Stimulation Conference, taking place December 6 - 9 in Charleston, S.C.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced positive results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 clinical trial of FTX-6058.

Aziyo Biologics, Inc. (the “Company”) today announced that it has entered into a definitive agreement to sell securities in a private placement that is expected to result in gross proceeds to the Company of approximately $14.0 million, before deducting offering expenses.

Autolus Therapeutics plc today announced it will hold a conference call to discuss the data being presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021.

ASLAN Pharmaceuticals today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials.